| CAS NO: | 112809-51-5 |
| 包装 | 价格(元) |
| 10mM (in 1mL DMSO) | 电议 |
| 100mg | 电议 |
| Cas No. | 112809-51-5 |
| 别名 | 来曲唑; CGS 20267 |
| 化学名 | 4-[(4-cyanophenyl)-(1,2,4-triazol-1-yl)methyl]benzonitrile |
| Canonical SMILES | C1=CC(=CC=C1C#N)C(C2=CC=C(C=C2)C#N)N3C=NC=N3 |
| 分子式 | C17H11N5 |
| 分子量 | 285.3 |
| 溶解度 | ≥ 14.265mg/mL in DMSO |
| 储存条件 | Store at -20℃ |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | Letrozole is a novel and potent type (II) aromatase inhibitor with IC50 of 11.5 nM. It belongs to the reversible non-steroidal compound family which can inhibit Arom. However, there is no evidence that it can affect the adrenal steroidogenesis.[1] Normally, Type II inhibitors have a common feature of heterocyclic azole moiety, which can be binded to the heme–iron in aromatase. It contains a structure of 1,2,4-triazole moieties which can coordinate the heme–iron of cytochrome P450. Meanwhile, benzonitrile substituted letrozole can mimic a unique enzyme structure of the substrate androstenedione.[2] Letrozole administration can reduce spine synapse and axon outgrowth and it also will decrease the expression of estrogen receptor ? (ER?). While, the synaptic proteins including GAP-43 can impaire the long-termpotentiation.[1] Letrozole is proved to promote FSH release from the hypothalamic pituitary axis by responding to decreased estrogen (E) feedback.[3] References: |
m.cnreagent.com